How Much Does Enclomiphene Citrate Cost in Montana in 2026?

Why Enclomiphene Citrate Pricing in Montana Differs from Other States

Montana residents pay roughly $90 per month for compounded enclomiphene citrate through 503A pharmacies, a figure that aligns with the national average for compounded formulations. Because no FDA-approved enclomiphene product currently exists on the U.S. market, pricing is driven almost entirely by compounding pharmacy economics rather than manufacturer list prices.

The absence of a branded product creates a pricing structure unlike most prescription drugs. There is no wholesale acquisition cost (WAC) to anchor negotiations between insurers and pharmacies. Instead, 503A compounding pharmacies set prices based on raw ingredient cost, compounding labor, and state-specific licensing fees. Montana's Board of Pharmacy regulates these facilities under 21 USC §503A, which requires a patient-specific prescription and an established prescriber-patient relationship.

Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that has been used off-label for male hypogonadism for decades. A 2016 study by Kim et al. in BJU International demonstrated that enclomiphene citrate significantly raised testosterone levels while preserving spermatogenesis in men with secondary hypogonadism 1. That pharmacologic profile makes it attractive for younger men who want to avoid the fertility suppression associated with exogenous testosterone.

Price variation across Montana pharmacies is modest. Most 503A compounding pharmacies in the state charge between $80 and $110 per month depending on capsule strength and dispensing volume. A 90-day supply sometimes brings per-month costs down to $75.

Montana Medicaid and Enclomiphene Citrate: What's Covered

Montana Medicaid does not cover enclomiphene citrate. The drug lacks FDA approval as a standalone product, and Montana's Medicaid formulary does not include compounded medications that fall outside standard Medicaid rebate agreements.

This exclusion is consistent across nearly all state Medicaid programs. The Medicaid Drug Rebate Program, administered by CMS, requires manufacturers to sign rebate agreements with the federal government before a drug can appear on a state's covered drug list. Since no manufacturer holds an NDA for enclomiphene citrate, there is no rebate agreement in place, and compounding pharmacies cannot participate in this program.

Montana Medicaid does cover clomiphene citrate (the racemic mixture containing both enclomiphene and zuclomiphene isomers) for certain approved indications, primarily female ovulatory dysfunction. Men prescribed clomiphene off-label for hypogonadism may find partial coverage under prior authorization, but this varies by managed care organization. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism acknowledges clomiphene as an alternative but does not specifically recommend enclomiphene due to its regulatory status 2.

For Medicaid enrollees seeking testosterone optimization without exogenous testosterone, discussing racemic clomiphene citrate with a prescriber remains the most financially viable path.

Insurance Coverage for Enclomiphene in Montana

Most commercial insurance plans in Montana do not reimburse enclomiphene citrate. The reason is straightforward: insurers typically exclude compounded drugs from standard pharmacy benefits unless a medically necessary exception is approved.

Some self-funded employer plans in Montana have broader compounding coverage. These plans, governed by ERISA rather than state insurance mandates, can design formularies that include 503A compounded products. Employees at larger Montana employers (Billings Clinic, Montana State University, NorthWestern Energy) should check their specific plan documents or call the pharmacy benefit manager directly.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for compounded enclomiphene citrate when prescribed by a licensed provider. The IRS classifies prescription compounded medications as qualified medical expenses under IRS Publication 502. For Montana residents in high-deductible health plans, this effectively provides a 22% to 37% discount depending on marginal tax bracket.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's hypogonadism guideline, has stated: "Selective estrogen receptor modulators like clomiphene and its isomers offer a fertility-sparing alternative to testosterone, but patients need to understand that insurance coverage for these agents remains inconsistent" 2.

Blue Cross Blue Shield of Montana, the state's largest commercial insurer, categorizes compounded medications under a general exclusion unless the prescriber submits documentation that no FDA-approved equivalent exists for the specific clinical indication. Since clomiphene citrate (Clomid) is FDA-approved and pharmacologically related, most appeals for enclomiphene coverage are denied.

Compounded Enclomiphene Citrate Legality in Montana

Compounded enclomiphene citrate is legal to prescribe and dispense in Montana through 503A-licensed compounding pharmacies. Montana law follows the federal framework established by the Drug Quality and Security Act (DQSA) of 2013, which permits patient-specific compounding under Section 503A of the FD&C Act.

Three conditions must be met. First, a licensed prescriber must write an individual prescription based on a clinical evaluation. Second, the compounding pharmacy must hold a valid Montana Board of Pharmacy license. Third, the compounded product cannot be a copy of a commercially available FDA-approved drug. Since no standalone enclomiphene citrate product is FDA-approved, compounding pharmacies can legally prepare it.

Montana does not currently have a state-level ban or restriction on enclomiphene compounding, unlike a small number of states that have imposed additional requirements on SERM compounding. The FDA's bulk drug substance list does not include enclomiphene citrate as a nominated substance under 503B outsourcing facility provisions, which means 503B facilities cannot compound it without patient-specific prescriptions 3.

The distinction matters. A 503A pharmacy in Bozeman or Helena can fill your individual prescription. A 503B outsourcing facility cannot produce enclomiphene in bulk without specific FDA authorization.

Getting Enclomiphene via Telehealth in Montana

Telehealth prescribing of enclomiphene citrate is fully legal in Montana, and it represents the most common access pathway for residents outside the state's urban centers. Montana's population density of just 7.5 people per square mile means many residents live hours from the nearest endocrinologist.

Montana's telehealth parity law (MCA 33-22-138) requires insurers to cover telehealth visits at the same rate as in-person visits. While the drug itself may not be covered, the consultation to obtain the prescription is a standard covered medical visit for most insured Montanans.

A typical telehealth workflow for enclomiphene in Montana follows this sequence: initial video consultation with blood work review (total testosterone, LH, FSH, estradiol), prescription sent electronically to a licensed 503A compounding pharmacy, and follow-up labs at 6 to 8 weeks. The American Urological Association's 2018 guideline on male infertility recommends baseline and follow-up hormonal panels when initiating SERMs for hypogonadism 4.

Telehealth platforms that operate in Montana must hold appropriate state licensure. The Montana Board of Medical Examiners requires out-of-state telehealth prescribers to obtain a Montana telemedicine license or a full Montana medical license. Patients should verify their telehealth provider's Montana credentials before beginning treatment.

How to Find the Cheapest Enclomiphene Citrate in Montana

The most cost-effective approach combines three strategies: selecting a high-volume 503A compounding pharmacy, ordering a 90-day supply, and using pre-tax health account dollars.

Compounding pharmacies that process higher volumes of enclomiphene prescriptions typically offer lower per-unit pricing. In Montana, pharmacies in Billings and Missoula tend to have the highest enclomiphene prescription volume, which translates to modestly lower prices (often $80 to $85 per month versus $95 to $110 at lower-volume pharmacies).

Ordering a 90-day supply reduces per-month cost by approximately 10% to 15% at most compounding pharmacies. A single 90-day dispensing also cuts shipping costs for patients who use out-of-state compounding pharmacies that ship to Montana.

The total annual cost of enclomiphene citrate in Montana, assuming $90 per month, is $1,080. Paying with HSA or FSA funds at a 24% marginal tax rate saves approximately $259 per year, bringing the effective annual cost to roughly $821. That figure compares favorably to testosterone cypionate injections ($40 to $100 per month for the medication alone) while preserving fertility, an important consideration given that the Kim et al. study found enclomiphene maintained sperm concentration at or above baseline levels throughout treatment 1.

Discount programs from telehealth platforms occasionally reduce the combined cost of consultation plus medication. Some platforms bundle the prescriber visit and a 30-day compounded supply for $129 to $149, which may be less expensive than paying separately for a specialist visit ($150 to $300 without insurance) and a standalone compounding pharmacy fill.

Enclomiphene Citrate vs. Testosterone Replacement: Cost Comparison in Montana

Men weighing enclomiphene against testosterone replacement therapy (TRT) in Montana should compare total cost of care, not just medication price. TRT involves ongoing monitoring costs that enclomiphene partially avoids.

Testosterone cypionate injections, the most common TRT formulation, cost $40 to $100 per month at Montana pharmacies for the generic injectable. But TRT also requires monitoring of hematocrit every 6 to 12 months (risk of polycythemia), PSA screening, and periodic semen analysis if fertility preservation matters. A single hematocrit panel at a Montana lab runs $15 to $50 out of pocket.

Enclomiphene requires testosterone level monitoring and liver function tests, but it does not carry the polycythemia risk that necessitates frequent hematocrit checks 1. The Endocrine Society guideline recommends hematocrit monitoring at 3 to 6 months and then annually for men on exogenous testosterone 2.

The American Urological Association has noted: "In men desiring fertility, alternatives to exogenous testosterone, including selective estrogen receptor modulators, should be considered as first-line therapy for hypogonadism" 4. This recommendation carries particular weight for Montana men in their 20s and 30s who have not yet completed family planning.

On a pure medication-cost basis, TRT is often cheaper. On a total-cost-of-care basis that includes monitoring and potential fertility preservation procedures (sperm banking costs $300 to $1,000 for initial collection plus $200 to $500 annually for storage in Montana), enclomiphene may be the more economical choice for men who value fertility.

What to Expect: Starting Enclomiphene Citrate in Montana

Most Montana prescribers initiate enclomiphene citrate at 12.5 mg or 25 mg once daily. The capsule is taken orally, typically in the morning. Steady-state testosterone elevation occurs within 2 to 4 weeks in most men.

Pre-treatment lab requirements include total testosterone (drawn between 7:00 and 10:00 AM on two separate mornings), LH, FSH, estradiol, a comprehensive metabolic panel, and a lipid panel. The Endocrine Society recommends confirming hypogonadism with two separate morning testosterone measurements before initiating any hormonal therapy 2.

Follow-up labs at 6 to 8 weeks assess testosterone response and estradiol levels. Some men experience a rise in estradiol due to increased aromatization of newly elevated testosterone. If estradiol rises above 40 to 50 pg/mL with associated symptoms (breast tenderness, water retention), the prescriber may adjust the dose or add a low-dose aromatase inhibitor.

Side effects reported in clinical trials include headache (5% to 8%), hot flashes (3% to 5%), and visual disturbances (rare, <1%). The visual side effects seen with racemic clomiphene appear less frequently with the isolated enclomiphene isomer, though head-to-head safety data remains limited 1.

Montana patients using telehealth can complete follow-up blood draws at any Quest Diagnostics or Labcorp location in the state, with results sent directly to the prescribing provider. Quest operates locations in Billings, Great Falls, Helena, and Missoula. Labcorp has a smaller Montana footprint but accepts mobile phlebotomy orders for rural patients at an additional fee of $25 to $50.